Publication | Closed Access

Antitumoral actions of the anti-obesity drug orlistat (Xenical™) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene

Breast OncologyOncologyCell Cycle ProgressionMedicineBreast Cancer CellsPharmacologyCancer Cell BiologyCell DeathBreast CancerCancer BiologyCell BiologyAnti-obesity Drug OrlistatTumor Biology